Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q2 FY27 revenue INR 130.45 Cr; EBITDA INR 19.2 Cr (14.72% margin); PAT INR 8.78 Cr (6.82% margin) - MCC capacity expansion of 12,000 MT expected Q2 FY28, total MCC capacity ~30,000 MT - New PureCoat coatings launched addressing pharma industry needs - FY27 revenue guidance revised to ~INR 600 Cr from INR 650 Cr due to project delay; EBITDA margin guidance ~18% - API business capacity 100 kL, targeting INR 90-120 Cr revenue with new products sparsentan and bempedoic acid - Capacity utilization ~80% in MCC; expected to reach 90-95% by Q3/Q4 FY27 with safety upgrades completed - Capex of ~INR 200 Cr planned for MCC and CCS projects, funded by internal accruals, insurance claims, and possible debt/equity - Preferential share issue canceled due to price rise; fundraise options under consideration - Management confident on demand, competitive positioning, and margin improvement in H2 FY27